Fig. 5: CD4+ T cells improved the functions of CIK cells through IL-17A.
From: CD4+ T cells are required to improve the efficacy of CIK therapy in non-small cell lung cancer
A Western blot analysis of STAT3, AKT, and ERK phosphorylation in CD4-CIK cells stimulated with rIL-17 (100 ng/ml) protein for 2 h. B The cytotoxicity of CD4-CIK cells treated with or without rIL-17 against A549. C, D Flow cytometric analysis of Tim-3 and GzmB expression in CD3+CD8+ T and CD3+CD8+CD56+ T cells treated with AKT inhibitor (Ly294002, 10 μM), rIL-17 or PBS. E Relative mRNA quantification of Eomes and T-bet in CD4−CIK cells treated with rIL-17, inhAKT, or PBS for 72 h. F Correlation analysis of IL-17A and CD8+ T cells infiltration or NK cells activated infiltration in LUAD and LUSC in TIMER public database. G Correlation analysis of IL-17A and EOMES or TBX21 in LUAD and LUSC in TIMER public database. H Flow cytometric examination of IL-17 and IFN-γ production in CIK cells before and after ex vivo expansion. I, J The relationship of Th1 and Th17 cell groups (n = 8). K Flow cytometric analysis of Tim-3 expression in CD3+CD8+ T and CD3+CD8+CD56+ T cells treated with tumor-conditioned medium in the presence of Th17 cells, CD4+ T cells or absence of these cells. L Flow cytometric determination of GzmB production in CD3+CD8+ T and CD3+CD8+CD56+ T cells. M Relative mRNA quantification of Tox, Eomes, and T-bet in CD4−CIK cells treated with tumor-conditioned medium for 72 h. Error bars indicate SEM, *P < 0.05, **P < 0.01, ***P < 0.001, and ****P < 0.0001 (one-way ANOVA or Student's t test).
